References

Warning: The NCBI web site requires JavaScript to function. more...

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Pharmacoeconomic Report: Nintedanib (Ofev): Boehringer Ingelheim Canada Ltd. Indication: Chronic Fibrosing Interstitial Lung Diseases [Internet] Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2021 Apr.

Cover of Pharmacoeconomic Report: Nintedanib (Ofev)

Pharmacoeconomic Report: Nintedanib (Ofev): Boehringer Ingelheim Canada Ltd. Indication: Chronic Fibrosing Interstitial Lung Diseases [Internet]

Show details

Contents

< PrevNext >

References

1.: Richeldi L, Du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–2082. [PubMed: 24836310]
2.: Pharmacoeconomic analysis for ofev (nintedanib) for the treatment of chronic fibrosing interstitial lung disease with a progressive phenotype. In: CDR submission: ofev (nintedanib), 100 mg and 150 mg capsules (as nintedanib esilate) [CONFIDENTIAL sponsor’s submission]. Burlington (ON): Boehringer Ingelheim (Canada) Ltd.; 2020 Jul 24.
3.: Ofev (nintedanib capsules): 100 mg and 150 mg nintedanib (as nintedanib esilate) Protein Kinase Inhibitor [product monograph]. Burlington (ON): Boehringer Ingelheim (Canada) Ltd.; 2020 May 19.
4.: Clinical Study Report: c26471552-02. INBUILD®: A double-blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nintedanib over 52 weeks in patients with progressive fibrosing interstitial lung disease (PF-ILD). [CONFIDENTIAL internal sponsor’s report]. Ingelheim am Rhein (Germany): Boehringer Ingelheim International; 2019 Aug 15.
5.: Ontario Case Costing Initiative (OCCI). Toronto (ON): Ontario Health and Long-Term Care; 2018: https://www.ontario.ca/data/ontario-case-costing-initiative-occi. Accessed 2020 Oct 29.
6.: Ontario Ministry of Health Long-Term Care. Schedule of benefits for laboratory services. Toronto (ON): The Ministry of Health and Long-Term Care; 2019: http://www.health.gov.on.ca/en/pro/programs/ohip/sob/lab/lab_mn2019.pdf. Accessed 2020 Oct 29.
7.: Ontario Ministry of Health Long-Term Care. Ontario drug benefit formulary/comparative drug index. 2019; https://www.formulary.health.gov.on.ca/formulary/. Accessed 2020 Oct 6.
8.: Goodridge D, Lawson J, Duggleby W, Marciniuk D, Rennie D, Stang M. Health care utilization of patients with chronic obstructive pulmonary disease and lung cancer in the last 12 months of life. Respir Med. 2008;102(6):885–891. [PubMed: 18313278]
9.: Fassbender K, Fainsinger RL, Carson M, Finegan BA. Cost trajectories at the end of life: the Canadian experience. J Pain Symptom Manage. 2009;38(1):75–80. [PubMed: 19615630]
10.: Home care services. Facts & figures - publicly funded home care. Hamilton (ON): Home Care Ontario; 2014: https://www.homecareontario.ca/home-care-services/facts-figures/publiclyfundedhomecare Accessed 2020 Apr 28.
11.: Kondoh Y, Taniguchi H, Katsuta T, et al. Risk factors of acute exacerbation of idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2010;27(2):103–110. [PubMed: 21319592]
12.: Nintedanib (Ofev). (CADTH Common Drug Review clinical review report). Ottawa (ON): CADTH; [currently under review].
13.: Boehringer Ingelheim Ltd. response to October 6th 2020 CDR request for additional information regarding the Ofev CDR review [CONFIDENTIAL additional sponsor’s information]. Burlington (ON): Boehringer Ingelheim (Canada) Ltd.; 2020 Oct 14.
14.: Health Canada reviewer’s report: Ofev (nintedanib) [CONFIDENTIAL internal report]. Ottawa (ON): Therapeutics Products Directorate, Health Canada; 2020.
15.: CADTH Canadian Drug Expert Committee (CDEC) final recommendation: nintedanib (Ofev - Boehringer Ingelheim Canada Ltd.). Ottawa (ON): CADTH; 2015 Oct 15: https://www.cadth.ca/sites/default/files/cdr/complete/SR0426_Ofev_Oct-19-15.pdf. Accessed 2020 Nov 4.
16.: Ontario Ministry of Health Long-Term Care. Formulary Exceptional Access Program (EAP). 2020; http://www.health.gov.on.ca/en/pro/programs/drugs/odbf/odbf_except_access.aspx. Accessed 2020 Oct 15.
17.: CADTH Canadian Drug Expert Committee (CDEC) final recommendation: pirfenidone resubmission (Esbriet-Hoffmann-La Roche Limited). Ottawa (ON): CADTH; 2015 Apr 15: https://www.cadth.ca/sites/default/files/cdr/complete/cdr_compelte_SR0393_Esbriet_Apr-17-15.pdf. Accessed 2020 Oct 29.
18.: Saskatchewan Drug Plan. Saskatchewan online formulary database. 2020; http://formulary.drugplan.ehealthsask.ca/SearchFormulary. Accessed 2020 Oct 29.
19.: DeltaPA. [Ottawa (ON)]: IQVIA; 2019: https://www.iqvia.com/. Accessed 2020 Aug 13.
20.: CDR submission: ofev (nintedanib), 100 mg and 150 mg capsules (as nintedanib esilate) [CONFIDENTIAL sponsor’s submission]. Burlington (ON): Boehringer Ingelheim (Canada) Ltd.; 2020 Jul 24.
21.: Sutherland G, Dinh T. Understanding the gap: a pan-Canadian analysis of prescription drug insurance coverage. Ottawa (ON): The Conference Board of Canada; 2017: https://www.conferenceboard.ca/temp/ac6d613a-0739-479f-bdfc-81b375f88d91/9326_Understanding-the-Gap__RPT.pdf. Accessed 2020 Oct 29.
22.: Budget impact analysis for ofev (nintedanib) for the treatment of chronic fibrosing interstitial lung disease with a progressive phenotype. In: CDR submission: ofev (nintedanib), 100 mg and 150 mg capsules (as nintedanib esilate) [CONFIDENTIAL sponsor’s submission]. Burlington (ON): Boehringer Ingelheim (Canada) Ltd.; 2020 Jul 24.
23.: Duchemann B, Annesi-Maesano I, Jacobe de Naurois C, et al. Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of Greater Paris. Eur Respir J. 2017;50(2). [PubMed: 28775045]

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK572547

Contents

< PrevNext >

PubReader
Print View
Cite this Page
Pharmacoeconomic Report: Nintedanib (Ofev): Boehringer Ingelheim Canada Ltd. Indication: Chronic Fibrosing Interstitial Lung Diseases [Internet] Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2021 Apr. References.
PDF version of this title (882K)